Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$68.70 - $156.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)2.24M
Market Cap
$15.71B
Enterprise Value$15.82B
Total Cash (Recent Filing)$1.24B
Total Debt (Recent Filing)$2.61B
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Jul 31, 2025EPS Estimate
1.01Last Dividend Ex-Date
Jun 25, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding158,300,000
10 Day Avg. Volume2,023,231
30 Day Avg. Volume2,242,279
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)6.08
Price to Sales (P/S)0.00
P/FCF Ratio16.48
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue0.90
Enterprise Value/Gross Profit5.50
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$110.40Price Target Upside11.23% Upside
Rating ConsensusHold
Number of Analyst Covering17
Illumina News
Bulls Say, Bears Say
Bulls Say
Product ExpansionOwning SomaLogic IP outright will enable ILMN to accelerate product launches, including low to mid throughput panels and kits for other sample types.
Revenue GrowthThe acquisition of SomaLogic is expected to be accretive to growth, with high single-digit to low double-digit growth driven primarily by kit sales.
Strategic AcquisitionThe acquisition of SomaLogic is seen as a solid strategic fit for Illumina, particularly given their prior relationship and the potential synergies over time.
Bears Say
Competitive LandscapeThe market for proteomics remains competitive despite the acquisition enhancing Illumina's position within the ecosystem.
Earnings DilutionThe transaction is expected to be dilutive in the near term and won't be accretive to earnings until 2028 or beyond.
Market UncertaintyThere is uncertainty in the proteomics market dynamics and potential incremental margin dilution from the acquisition of SomaLogic.
Ownership Overview
2.71% Insiders
31.21% Mutual Funds
41.91% Other Institutional Investors
0.55% Public Companies and Individual Investors
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $156.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $15.71B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Jul 31, 2025 which is in 17 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on May 08, 2025. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.03.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina pays a Notavailable dividend of $3.104 which represents an annual dividend yield of N/A. See more information on Illumina dividends here
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.01.
How many shares outstanding does Illumina have?
Illumina has 158,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $0.97 in its last earnings report, beating expectations of $0.94. Following the earnings report the stock price went down -4.8%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$110.40 (11.23% Upside)
$110.40 (11.23% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.88%
12-Months-Change
Fundamentals
Return on Equity
-23.82%
Trailing 12-Months
Asset Growth
-38.43%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. is a leading biotechnology company that specializes in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company primarily operates in the genomics sector, providing innovative sequencing and array-based solutions that are used in a variety of applications including genetic research, clinical diagnostics, agriculture, and forensics. Illumina's core products include sequencing systems, consumables, and software that support researchers and clinicians in their pursuit of groundbreaking discoveries and advancements in personalized medicine.
ILMN Company Deck
ILMN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong performance in certain areas like NovaSeq X placements and innovation pipeline advancements, but significant challenges in the Greater China region, research funding uncertainty, and tariff impacts. While growth areas show promise, the lowlights pose substantial risks.Read More>ILMN Revenue Breakdown
91.33% Sequencing
8.67% Microarray
ILMN Stock 12 Month Forecast
Average Price Target
$110.40
▲(11.23%Upside)